Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (35)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Loumaye, E.
Right arrow Articles by on behalf of the Recombinant LH Study Group,
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loumaye, E.
Right arrow Articles by on behalf of the Recombinant LH Study Group,
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 18, No. 2, 314-322, February 2003
© 2003 European Society of Human Reproduction and Embryology

Clinical evidence for an LH ‘ceiling’ effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation

Ernest Loumaye1, Patrick Engrand1,4, Zeev Shoham2, Stephen G. Hillier3, David T. Baird3 and on behalf of the Recombinant LH Study Group*

1 Serono International, Reproductive Health Clinical Development Unit, Geneva, Switzerland, 2 Department of Obstetrics and Gynecology, Kaplan Medical Center, Rehovot, Israel and 3 Department of Obstetrics and Gynaecology, University of Edinburgh Centre for Reproductive Biology, Edinburgh, UK

4 To whom correspondence should be addressed at: Serono International, 15bis Chemin des Mines, CH-1202 Geneva, Switzerland

BACKGROUND: The objective of these studies was to test the hypothesis that over-dosing with recombinant human LH (rLH) during the late follicular phase would suppress the development of follicles. METHODS: Two double-blind studies were conducted. In study A, WHO I anovulatory patients received treatment with rFSH and rLH. When at least one follicle reached a mean diameter of 10–13 mm, patients were randomized using a computer-generated randomization list (stratified by centre) to rFSH and rLH (225 IU/day) (n = 8) or rLH alone (n = 6) or rFSH alone (n = 6). In study B, WHO II anovulatory patients with a hyper-responsive FSH were randomized to rLH (225 IU/day) (n = 4) or rLH 450 IU/day (n = 8) or placebo (n = 5). RESULTS: Study A: the mean number of follicles >=11 mm was 4.2 ± 0.3 in the rFSH group, 1.5 ± 0.7 in the rLH group and 6.0 ± 2.3 in the rFSH/rLH group (P = 0.07). 0/8 patients presented follicular growth arrest in the rFSH group, but 4/6 in the rLH group and 1/6 in the rFSH/rLH did. Study B: 5/12 patients presented follicular growth arrest in the rLH groups, but none in the placebo group. The mean number of follicles >=11 mm was 4.6 ± 1.8 for the placebo group, 2.5 ± 1.9 for the rLH 225 IU group and 4.2 ± 1.4 in the rLH 450 IU group (not significant). CONCLUSIONS: Results of this pilot study suggest that rLH alone can trigger follicular growth arrest in a significant number of patients, suggesting the existence of an ‘LH ceiling’ during late follicular maturation.

Key words: anovulation/follicular growth/recombinant FSH/recombinant LH

* Clinical Investigators: Prof. S.Franks, London, UK, Prof. D.Baird Edinburgh, UK; Prof. S.Smith, Cambridge, UK; Prof. R.Homburg, Israel; Prof. C.Flamigni and Dr M.Filicori, Bologna, Italy; Dr Fusi, Pisa, Italy; Prof. J.Schoemaker, Amsterdam, The Netherlands. These studies were partially presented at the Annual Meeting of the European Society of Human Reproduction and Embryology in Bologna, 2000 (Abstracts).


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Hum ReprodHome page
S. Ziebe, K. Lundin, R. Janssens, L. Helmgaard, J.-C. Arce, and for the MERIT (Menotrophin vs Recombinant FSH in v
Influence of ovarian stimulation with HP-hMG or recombinant FSH on embryo quality parameters in patients undergoing IVF
Hum. Reprod., September 1, 2007; 22(9): 2404 - 2413.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J. Smitz, A.N. Andersen, P. Devroey, J.-C. Arce, and for the MERIT Group
Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients
Hum. Reprod., March 1, 2007; 22(3): 676 - 687.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
P. Platteau, A. N. Andersen, A. Balen, P. Devroey, P. Sorensen, L. Helmgaard, J.-C. Arce, and for the Menopur Ovulation Induction (MOI) Study Gr
Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study
Hum. Reprod., July 1, 2006; 21(7): 1798 - 1804.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser
The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization
Endocr. Rev., April 1, 2006; 27(2): 170 - 207.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
I. E. Messinis
Ovulation induction: a mini review
Hum. Reprod., October 1, 2005; 20(10): 2688 - 2697.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J.N. Hugues, J. Soussis, I. Calderon, J. Balasch, R.A. Anderson, A. Romeu, and on behalf of the Recombinant LH Study Group
Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study
Hum. Reprod., March 1, 2005; 20(3): 629 - 635.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J. A.F. Huirne, A. C.D. van Loenen, R. Schats, J. McDonnell, P. G.A. Hompes, J. Schoemaker, R. Homburg, and C. B. Lambalk
Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy
Hum. Reprod., February 1, 2005; 20(2): 359 - 367.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
E. Loumaye
Reply: LH/HCG as a monthly injectable contraceptive
Hum. Reprod., May 1, 2004; 19(5): 1237 - 1237.
[Full Text] [PDF]


Home page
Hum ReprodHome page
H. N. Sallam and A. N. Sallam
LH/HCG as a monthly injectable contraceptive?
Hum. Reprod., April 1, 2004; 19(4): 1038 - 1038.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. J. Zeleznik, L. Little-Ihrig, and S. Ramasawamy
Administration of Dihydrotestosterone to Rhesus Monkeys Inhibits Gonadotropin-Stimulated Ovarian Steroidogenesis
J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 860 - 866.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J. Y.-P. Ho, J.-L. Hwang, M.-J. Chen, H.-F. Guu, and E. S.-C. Ho
What is the LH ceiling level for follicular growth arrest in late follicular phase?
Hum. Reprod., February 1, 2004; 19(2): 463 - 464.
[Full Text] [PDF]


Home page
Hum ReprodHome page
E. Loumaye, P. Engrand, Z. Shoham, S.G. Hillier, and D.T. Baird
Clinical evidence for an LH ceiling?
Hum. Reprod., December 1, 2003; 18(12): 2719 - 2720.
[Full Text] [PDF]


Home page
Hum ReprodHome page
M. Filicori, G. E. Cognigni, and W. Ciampaglia
What clinical evidence for an LH ceiling?
Hum. Reprod., July 1, 2003; 18(7): 1556 - 1557.
[Full Text] [PDF]


Home page
Hum ReprodHome page
J. Tesarik
Effects of LH on oocyte yield and developmental competence
Hum. Reprod., June 1, 2003; 18(6): 1358 - 1360.
[Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.